More context, better questions

Melanotan I is a historical development name associated with afamelanotide. The regulated afamelanotide implant Scenesse is approved in the United States for increasing pain-free light exposure in adults with erythropoietic protoporphyria and a history of phototoxic reactions. It should not be confused with unapproved tanning products.

GHK-Cu is a copper-binding tripeptide studied in skin biology and used in cosmetic formulations. The topical cosmetic ingredient and an injected preparation are different exposures. Evidence about one route should not be used to imply that the other has equivalent benefit or safety.

Afamelanotide activates the melanocortin-1 receptor and promotes eumelanin production. The clinical aim in erythropoietic protoporphyria is protection from painful phototoxic reactions, not recreational tanning. The controlled-release implant and the rare-disease context are essential parts of the treatment being evaluated.

The GHK sequence binds copper, and experiments explore effects on skin-related cellular signaling and tissue remodeling. Copper is a biologically active metal, while the peptide influences its chemical context. Skin penetration, formulation stability, concentration, and delivery method all affect the exposure actually produced by a topical product.

Approval is supported by studies in adults with erythropoietic protoporphyria. Outcomes such as pain-free time in sunlight relate to that disease and its burden. They do not establish a cosmetic tanning indication or demonstrate that a vial sold as melanotan is chemically or clinically equivalent to Scenesse.

Laboratory studies include skin models, cultured cells, and delivery experiments. These can identify possible mechanisms and formulation challenges. A cosmetic claim about appearance is also different from a treatment claim about a wound, a disease, or hair loss. Each needs relevant evidence using the actual finished product.

The historical name can obscure major differences in formulation, manufacturer, quality controls, administration, and intended use. Comparing photographs of darker skin does not substitute for clinical endpoints or safety follow-up. An approved implant administered by trained professionals is a different proposition from a self-mixed research product.

A favorable cell-culture result does not tell readers how large or durable a visible improvement will be. Many cosmetic products contain several active ingredients, making it difficult to attribute an observed effect specifically to GHK-Cu. Before-and-after photographs are vulnerable to differences in lighting, skin care, timing, and image selection.

The label addresses hypersensitivity, including serious reactions, and increased pigmentation or changes in existing pigmented lesions. Skin monitoring is relevant. Protection from one source of phototoxicity does not justify unrestricted ultraviolet exposure. Patients still need individualized advice about sun exposure and skin surveillance.

Topical irritation or allergy is possible, and damaged skin can change exposure. Injectable GHK-Cu introduces additional concerns that cannot be answered by topical testing. FDA has highlighted limited safety information and possible problems with aggregation and peptide impurities for injectable routes.

Scenesse is an FDA-approved prescription implant for its specific indication. This does not make all products marketed as Melanotan I approved. Regulatory status belongs to the exact product and use, not to a loosely shared nickname.

Cosmetic use does not equal FDA approval as a medicine. GHK-Cu should not be marketed as an FDA-approved injectable anti-aging or hair-restoration treatment. The intended claim and route matter when considering regulatory status.